Spotlight On... Thousands of blind Indians using an indigenous, low-cost 'smart' cane to avoid obstacles; BD gets FDA approval for cervical cancer screener; Palmaz declares bankruptcy, seeks partners; and more...

By attaching an ultrasonic sensor to the top of the white cane used by the blind to detect obstacles, Indian engineer Rohan Paul has reduced upper body collisions by 90% among 200 people who tested the device. More than 10,000 Indians now use the smart cane, which costs $50. "People have been trying to put sensors on canes for a very long time, but there was still an unmet need for a low-cost, effective, usable device," Paul, now a postdoctoral fellow at MIT, said. More

@FierceMedDev: ICYMI: Siemens Healthcare CEO: restructured unit 'hungry' for M&A deals. Article | Follow @FierceMedDev

@EmilyWFierce: UPDATED: AZ stokes $45B sales hopes with expanded approval for breast cancer drug Faslodex. More | Follow @EmilyWFierce

> Becton Dickinson ($BDX) has received FDA approval for its BD Totalys MultiProcessor and BD Totalys SlidePrep instruments that further automates cervical cancer screening. More

> Palmaz Scientific, a maker of implantable devices including the Palmaz Stent, has declared Chapter 11 bankruptcy and is seeking strategic partners. More

> Micro-cap Bionik Laboratories ($BNLK) will buy robotic neurorehabilitation company Interactive Motion Technologies in an all-stock deal worth about $24 million. More

Biotech News

@FierceBiotech: Celldex's cancer vaccine Rintega implodes in glioblastoma PhIII. News | Follow @FierceBiotech

@JohnCFierce: AbbVie hands over $595M upfront to partner with Boehringer on PhIII psoriasis drug. Report | Follow @JohnCFierce

> Bristol-Myers prints a pair of 'Golden Tickets' for Cambridge biotech startups. Report

> Europe takes a page from the FDA with new speedy approval program. Story

> Aimmune's peanut allergy drug clears Phase II on the way to a pivotal test. Article

Pharma News

@FiercePharma: Heska's topsy-turvy year ends on a high note as earnings beat estimates. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: Victoza comes up big for Novo with key heart-risk lowering data. More | Follow @CarlyHFierce

> How Venezuela's meltdown delivered a mega-hit to Big Pharma: Reuters. Story

> The potential to restrict generics with REMS is growing and it doesn't bode well for biosimilars. More

> Big Pharma wields big influence in Kentucky for restrictive biosimilars law. Article

Pharma Marketing News

> With Allergan's Kybella campaign, Khloé Kardashian follows sister Kim into pharma land. Report

> New privacy-friendly partnership taps consumer data to help pharma target mobile marketing. Item

> J&J, AbbVie swell Imbruvica patient pool with first-line FDA nod in CLL. More

> DTC challenges mount as senators roll out bill to yank tax deduction. Story

> New privacy-friendly partnership taps consumer data to help pharma target mobile marketing. Article

Animal Health News

> Kindred projects increased spending as it preps for first commercial product. Item

> VCA adds 56 veterinary clinics by snapping up $344M stake in Las Vegas chain. Report

> Heska's topsy-turvy year ends on a high note as record earnings beat estimates. More

> Under pressure from activists, In-N-Out Burger jumps on antibiotic-free bandwagon. Story

> Zoetis launches first genomic test for predicting common diseases in Holsteins. Article

Biotech IT News

> Bristol-Myers signs deal to use Veeva tools for regulatory information. News

> U.K. firms team up to develop mental health-tracking wearable devices. Report

> GSK extends business process analytics contract to 2020. Story

> George Church's Veritas starts $999 whole-genome sequencing service. Item

> IPhone-based Parkinson's study shares 6 months of data on 9,500 participants. Article

Suggested Articles

BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.